Myelofibrosis Epidemiology Analysis and Forecast, 2021-2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Myelofibrosis Epidemiology Market Overview
In the 8MM, there were 69,236 diagnosed prevalent cases of Myelofibrosis (MF) in 2021. MF belongs to a group of diseases called myeloproliferative disorders. MF is a serious bone marrow disorder that disrupts the body’s normal production of blood cells (MedlinePlus, 2020; Mayo Clinic, 2021). MF includes primary MF (PMF), which is idiopathic. At times, essential thrombocytosis (ET) or polycythemia vera (PV) could progress to MF, resulting in post-essential thrombocytosis MF (PET MF) and post-polycythemia vera MF (PPV MF), which are referred to as secondary MF (SMF).
Myelofibrosis Epidemiology Market Overview, 2021-2031
For more insights in the Myelofibrosis epidemiology market, download a free report sample
The Myelofibrosis epidemiology market research report provides an overview of the risk factors, comorbidities, and the global and historical trends for MF in the eight major markets. It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of MF, PMF, PET MF, and PPV MF. That forecast is based on county-specific studies published in peer-reviewed journals. The report also offers sex-specific diagnosed incident and diagnosed prevalent cases of PET MF and PPV MF in the 8MM for the forecast period.
Market size 2021 | 69,236 cases |
AGR | >2% |
Key age segments | 40-49 Years, 50-59 Years, 60-69 Years, 70-79 Years, and 80 Years or Older |
Key Age Segments for Diagnosed Incident and Prevalent Cases of MF
The key age segments for the diagnosed incident and prevalent cases of MF are 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years or older. In 2021, for the 8MM combined, adults of 60–69 years contributed the highest proportion of the diagnosed incident and prevalent cases.
Diagnosed Incident and Prevalent Cases of MF, by Age Segments
For more age segment insights in the Myelofibrosis epidemiology market, download a free report sample
COVID-19 Impact on MF Epidemiology Market
Coronavirus disease 2019 (COVID-19) is likely to have far-reaching consequences as global healthcare systems have been redirected to focus on fighting the pandemic. The impact of the COVID-19 pandemic may include a shortage of medical staff, decreased access to treatment, a delay in diagnosis, decreased survival, and an increase in disease incidence related to coronavirus infections. There is too little known about the clinical outcomes of individuals with MPN who are infected with COVID-19. It is felt that patients with intermediate or high-risk MF may have a higher risk of adverse outcomes if they become infected with COVID-19.
Scope
This report:
- Provides an overview of the risk factors, comorbidities, and the global and historical trends for MF in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
- Includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of MF, PMF, PET MF, and PPV MF based on county-specific studies published in peer-reviewed journals. The report also provides sex-specific diagnosed incident and diagnosed prevalent cases of PET MF and PPV MF in the 8MM for the forecast period.
- Is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
- Showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
The Myelofibrosis Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global myelofibrosis market.
- Quantify patient populations in the global myelofibrosis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for myelofibrosis therapeutics in each of the markets covered.
- Understand the magnitude of myelofibrosis by risk categories, mutations, and anemia.
Table of Contents
Table
Figures
Frequently asked questions
-
What was the total number of prevalent cases of MF in 2021?
The total number of prevalent cases of MF was 69,236 in 2021.
-
What is the growth rate of the MF epidemiology market?
The MF epidemiology market is expected to grow at an AGR of more than 2%.
-
What are the key age segments in the MF epidemiology market?
The key age segments in the diagnosed incident and prevalent cases of MF are 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years or older.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.